Prescription medication · Aminoglycoside Antibiotic
plazomicin
Also sold as Zemdri. Zemdri treats complicated urinary tract infections (cUTIs) in adults, including kidney infections (pyelonephritis).
Data updated 2026-05-15
- 3
- FDA reportsRarely reported
- Rx
- Availability
plazomicin (Zemdri) is a prescription Aminoglycoside Antibiotic. Zemdri treats complicated urinary tract infections (cUTIs) in adults, including kidney infections (pyelonephritis).
Zemdri is an antibiotic medicine. It is used to treat complicated urinary tract infections.
Verify with FDA → · CMS NADAC pricing →
What it does
Zemdri treats complicated urinary tract infections (cUTIs) in adults, including kidney infections (pyelonephritis).
Common side effects
Decreased kidney function, Diarrhea, High blood pressure
Key warnings
Zemdri can cause serious side effects, including kidney damage, hearing loss, and muscle weakness.
The sections below are summarized in plain English from plazomicin's FDA-approved prescribing information. They describe what the official label says, and are not personal medical advice.
How It Works
Zemdri belongs to a class of drugs called aminoglycoside antibiotics. It works by stopping the growth of bacteria. This helps your body fight off the infection.
Side Effects (from patient reports)
Based on 3 FDA adverse event reports.
Most-reported reactions
Adverse reactions in FAERS for plazomicin, by number of reports
- Acute Kidney Injury
Acute Kidney Injury
1 reports
- Antibiotic Level Above Therapeutic
Antibiotic Level Above Therapeutic
1 reports
- Creatinine Renal Clearance Decreased
Creatinine Renal Clearance Decreased
1 reports
- Drug Effect Less Than Expected
Drug Effect Less Than Expected
1 reports
- Gastrointestinal Haemorrhage
Gastrointestinal Haemorrhage
1 reports
- Renal Failure
Renal Failure
1 reports
What this shows Bars show how often each reaction was reported, not how likely it is to happen, a report records a temporal association, never proof that the drug caused it.
Where plazomicin sits
plazomicin has more FDA adverse-event reports than 0% of the drugs FAERS tracks. A high position reflects how widely a drug is used and watched, not how dangerous it is.
Percentile across all drugs PlainMeds tracks by FAERS report volume. The dot is plazomicin; the line is the median (50th percentile).
FDA Adverse Event Report Analysis
Detailed analysis of 3 reports from the FDA Adverse Event Reporting System (FAERS). Reports span 2021–2022.
Total Reports
3
Hospitalization Reports
1
Top Indication
Infusion
Gender Distribution
Age Distribution
Most Reported Adverse Reactions (FAERS)
| # | Reaction | Reports |
|---|---|---|
| 1 | ACUTE KIDNEY INJURY | 1 |
| 2 | ANTIBIOTIC LEVEL ABOVE THERAPEUTIC | 1 |
| 3 | CREATININE RENAL CLEARANCE DECREASED | 1 |
| 4 | DRUG EFFECT LESS THAN EXPECTED | 1 |
| 5 | GASTROINTESTINAL HAEMORRHAGE | 1 |
| 6 | RENAL FAILURE | 1 |
Reactions in Hospitalization Reports
Source: FDA FAERS (Adverse Event Reporting System) Reports are voluntary and do not establish causation
Serious Warnings
Zemdri can cause serious side effects, including kidney damage, hearing loss, and muscle weakness. It can also harm an unborn baby. Tell your doctor if you have kidney problems, hearing problems, or are pregnant or plan to become pregnant.
Common Questions
What if I am allergic to Zemdri?
Can Zemdri affect my kidneys?
Can Zemdri affect my hearing?
Can Zemdri cause muscle weakness?
What should I tell my doctor before taking Zemdri?
What are the most common side effects of Zemdri?
How long will I need to take Zemdri?
How is Zemdri given?
What if I have kidney problems?
Can I take Zemdri with other medications?
What are the common side effects of plazomicin?
What drug class is plazomicin?
What pregnancy or breastfeeding source fields are listed for plazomicin?
Related Medications in Aminoglycoside Antibiotic
Other drugs grouped near plazomicin - same-class peers and common alternatives.
amikacin
Amikin
Amikacin is an antibiotic medicine.
Compare with plazomicin →
amoxicillin
Amoxil
Amoxicillin and Clavulanate Potassium is a combination medicine used to fight bacterial infections.
Compare with plazomicin →
amoxicillin/clavulanate
Augmentin
Augmentin is a combination of two medicines, amoxicillin and clavulanate.
Compare with plazomicin →
ampicillin/sulbactam
Unasyn
Unasyn is a combination of two antibiotics that fights bacteria in your body.
Compare with plazomicin →
azithromycin
Zithromax, Z-Pack
Azithromycin is an antibiotic that fights bacteria.
Compare with plazomicin →
Compare beyond drug class
Nationwide peers by FAERS volume & death-report share
Two PlainMeds-derived comparison paths for plazomicin: nearest FDA FAERS report volume and nearest death-report share among drugs with at least 1,000 logged reports, excluding same-class neighbors listed above. Counts reflect reporting volume, not proven individual harm.
Similar FAERS report volume
Nearest drugs by total FAERS reports. This record: 3.
Similar death-report share
Nearest drugs by FAERS death-report share. This record: 0.00%.
- adapalene Δ 0.02 pts · 178,147 reports · Retinoid (Topical) 0.02%death share
- levonorgestrel Δ 0.14 pts · 197,074 reports · Progestin 0.14%death share
- etonogestrel Δ 0.20 pts · 46,939 reports · Progestin (Implant) 0.20%death share
- crisaborole Δ 0.26 pts · 9,400 reports · PDE4 Inhibitor (Topical) 0.26%death share
Medication Guides
Understanding Drug Interactions
How CYP450 enzymes, inhibitors, and inducers affect your medications
Generic vs Brand Name Drugs
FDA requirements, cost savings, and when the difference matters
Narrow Therapeutic Index Drugs
FDA bioequivalence and label-record context for narrow therapeutic index medicines
Common Drug Interactions
Dangerous medication combinations and how to protect yourself
Save on plazomicin
Compare prices and find discounts at pharmacies near you. Free coupons can save up to 80% on prescriptions.
Disclosure: This link may earn us a commission at no extra cost to you. See our terms.
What the FDA Data Shows for plazomicin
The FDA label for plazomicin (sold under brand names such as Zemdri) classifies it as a prescription-only medication in the Aminoglycoside Antibiotic class. Zemdri treats complicated urinary tract infections (cUTIs) in adults, including kidney infections (pyelonephritis). Official labeling lists 7 commonly reported side effects, including Decreased kidney function, Diarrhea, High blood pressure.
Post-market surveillance from the FDA Adverse Event Reporting System (FAERS) captures real-world experience. For this drug, FAERS contains 3 voluntary reports. Interaction data is drawn directly from FDA-approved prescribing information. Acquisition-cost data is surveyed weekly by CMS and updated as manufacturers report changes.
Report counts do not establish causation, a FAERS entry documents a temporal association, not proof that the drug produced the outcome. Widely prescribed medications naturally accumulate more reports than niche therapies, so raw totals must be interpreted alongside total exposure. Shortage status, recall history, and patent information are separate source-record fields. This page is a public FDA/CMS registry and does not provide medical, treatment, substitution, or medication-change directions.
Data Sources
Drug labeling: FDA Drug Labels (SPL/DailyMed). Adverse events: FDA Adverse Event Reporting System (FAERS).
FAERS reports are voluntary and do not establish causation. Drug interactions are derived from FDA labeling and clinical references. This registry does not provide medication decisions.
Last updated: June 29, 2018
PlainMeds is rendered directly from FDA openFDA/FAERS extracts, DailyMed labels, and CMS drug-pricing files, no number is typed in by an editor. FAERS counts, recalls, shortages, and price figures on this page are queried live from those federal extracts. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-05-15. Primary sources: openFDA / FAERS, DailyMed and CMS Part B ASP.
Read our methodology - how this data is sourced, computed, and verified.
Data currency: FDA FAERS adverse-event reports through 2025, CMS NADAC acquisition-cost pricing effective December 2024, compiled from the source snapshot dated . See our methodology for per-source dates and refresh cadence. Spot a figure that looks wrong? Report a data issue.
All federal data sources used on this page
- FDA Orange Book - approved drug products with therapeutic equivalence. accessdata.fda.gov/cder/ob
- FDA DailyMed - NIH-hosted drug labeling for FDA-approved meds. dailymed.nlm.nih.gov
- FDA Adverse Event Reporting System (FAERS) - post-marketing safety surveillance. fda.gov/drugs/faers
- NLM RxNorm - standardized clinical drug nomenclature. nlm.nih.gov/research/umls/rxnorm
- CMS Medicare Part B Drug Average Sales Price Files - federal drug pricing data. cms.gov/medicare/part-b-drugs/asp
- FDA Drug Shortages Database - current and resolved drug shortage tracking. accessdata.fda.gov/drugshortages